The Translational Genomics Research Institute of Phoenix last week announced its governing board, which is headed by José Cárdenas, managing partner of the Phoenix law firm of Lewis and Roca. The board includes: Gov. Jane Hull (R-Ariz.); former Sen. Mark O. Hatfield (R-Ore.), Hamilton Jordan, former White House chief of staff; Peter Likens, president of the University of Arizona; Michael Crow, president of Arizona State University; and Franklyn Prendergast, director, the Mayo Clinic Cancer Center.
Inder Verma was named to the scientific advisory board of Nugen Technologies of San Carlos, Calif. Verma is currently a professor of molecular biology in the laboratory of genetics at the Salk Institute, as well as an adjunct professor in the department of biology at University of California, San Diego. He holds a PhD from the Weizmann Institute of Science in Israel and did postdoctoral study at the Massachusetts Institute of Technology. He is a member of the National Academy of Sciences, American Academy of Arts and Sciences, the Institute of Medicine, and the Third World Academy of Sciences, and is a March of Dimes Birth Defects Foundation Franklin D. Roosevelt Investigator.
Mark Emkjer has been named president of Accelrys of Princeton, NJ, a wholly owned subsidiary of Pharmacopeia. Emkjer was most recently presient and chief operating officer of Sunquest Information Systems. Prior to that, he was president and CEO of Pace Health Management Systems.
Whaijen Soo was named senior vice president, medical research, for Biogen. Soo will oversee all medical research activities, and he will also serve as a member of the research and development management team. He reports to Burt Adelman, executive vice president, research and development. Soo was vice president, clinical sciences for Roche. Soo holds a PhD in Biochemistry from the University of California at Berkeley. He attended the University of California at San Francisco Medical School and performed his residency at Brigham and Woman’s Hospital.